• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Ezetimibe

Ezetimibe

Product ID E9819
Cas No. 163222-33-1
Purity ≥99%
Product Unit SizeCostQuantityStock
25 mg $63.00 In stock
100 mg $176.40 In stock
250 mg $404.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Ezetimibe is an inhibitor of Niemann-Pick-like C1-type 1 (NPC1L1) protein, a cholesterol transport protein, resulting in inhibition of intestinal cholesterol transport and decreases in LDL levels. Ezetimibe exhibits anti-hyperlipidemic, anti-atherosclerotic, anti-diabetic, nephroprotective, and hepatoprotective activities. In hepatocytes, ezetimibe decreases mTORC1 activity and increases autophagy, decreasing free cholesterol in the plasma membrane. In other in vitro models, ezetimibe inhibits expression of intracellular adhesion molecule 1 (ICAM-1) and CD11A/B, phosphorylation of ERK, and activation of NF-κB, decreasing adhesion of THP-1 cells and preventing them from differentiating into macrophage-like cells. In animal models of diabetes, this compound normalizes adiponectin levels, decreases plasma and hepatic lipids, and improves glomerular hypertrophy. Additionally, ezetimibe decreases generation of ROS, downregulates expression of skp2 and CDC20, and inhibits degradation of microsomal triglyceride transfer protein (MTP), improving fibrosis and steatosis in animal models of nonalcoholic fatty liver disease.

Product Info

Cas No.

163222-33-1

Purity

≥99%

Formula

C24H21F2NO3

Formula Wt.

409.43

IUPAC Name

(3R, 4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4- hydroxyphenyl)azetidin-2-one

Melting Point

164-166°C

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

E9819 MSDS PDF

Info Sheet

E9819 Info Sheet PDF

References

Yamamura T, Ohsaki Y, Suzuki M, et al. Inhibition of NPC1L1 by ezetimibe activates autophagy in human hepatocyte and reduces mutant α1-antitrypsin Z deposition. Hepatology. 2013 Nov 9. [Epub ahead of print]. PMID: 24214142.

Wang X, Sugimoto K, Fujisawa T, et al. Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse. Hepatol Res. 2014 Jan;44(1):102-13. PMID: 23510093.

Muñoz-Pacheco P, Ortega-Hernández A, Miana M, et al. Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism. Pharmacol Res. 2012 Dec;66(6):536-43. PMID: 22989505.

Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415-27. PMID: 22910633.

Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8132-7. PMID: 15928087.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • R3476

    RITA

    p53 activator.

    ≥98%
  • E7433

    Etidronate Disodium

    Bisphosphonate, chelating agent.

    ≥98%
  • V5870

    Vortioxetine

    5-HT1A agonist, 5-HT1B partial agonist, 5-HT3A/...

    ≥99%
  • A6828

    N(α),N(α)-Dimethyl-L-Arginine Ammonium

    Endogenous amino acid derivative, regulates water/...
    ≥98%
  • G5320

    GNF-2

    Abl inhibitor.

    ≥98%
  • H1673

    Hesperidin

    Flavonoid found in species of Citrus; COX-2 inh...

    ≥95%
  • K740640

    KSQ-4279

    USP1 inhibitor

    ≥98%
  • N1986

    Neuropeptide Y, human/rat

    Endogenous peptide neurotransmitter, involved i...

    ≥95%
  • C4274

    CKS-17

    Synthetic peptide, retroviral envelope protein ...

    ≥95%
  • D3218

    Diethylstilbestrol

    Synthetic non-steroid endocrine disrupter; ER a...

    ≥98%
  • A9708

    AZD-1208

    Pim-1 inhibitor.

    ≥98%
  • N344786

    N-Nitroso Valsartan Methyl Ester

    Valsartan impurity

  • T6933

    Trichostatin A

    HDAC inhibitor, mammalian RNA splicing modulato...

    ≥98%
  • M2076

    Metformin Hydrochloride

    AMPK activator.

    ≥98%
  • R520002

    RN-1747

    TRPV4 agonist

    ≥98%
  • O938565

    6-Oxodocetaxel

    Docetaxel impurity

    ≥98%
  • N7604

    Naltriben

    δ2OR antagonist.

    ≥95%
  • D1869

    Deracoxib

    NSAID; COX-2 inhibitor.

    ≥99%
  • R2514

    RGDV

    Tretraeptide, binds cell surface integrins.

    ≥98%
  • P3597

    Pizotyline Malate

    5-HT1A partial agonist, 5-HT2C antagonist.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only